BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22252796)

  • 1. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
    Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
    Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J; Stähle H; Rathgen K; Fuhr R
    Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
    Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
    J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.
    Härtter S; Sennewald R; Schepers C; Baumann S; Fritsch H; Friedman J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):327-39. PubMed ID: 22782539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
    Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
    Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
    Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
    J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate in venous thromboembolism.
    Ferrer E
    Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
    McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
    Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
    J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
    Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
    Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
    Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
    Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options with dabigatran etexilate in anticoagulant therapy.
    Maegdefessel L; Spin JM; Azuma J; Tsao PS
    Vasc Health Risk Manag; 2010 May; 6():339-49. PubMed ID: 20531953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
    Stangier J
    Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.